Plasma and Intracellular Antiretroviral Concentrations in HIV-Infected Patients under Short Cycles of Antiretroviral Therapy

Table 1

Intracellular concentrations and intracellular/plasma concentration ratios.

	Time (h)^a	Median (range) fmol per 10^6 cells^b		Intracellular/plasma concentration ratios^c
ATV 300 mg	13	1685 559.3–4085	10	3.04 1.94–3.23	7
	85	76.4 63.9–87.7	3	nc^b
LPV 400 mg	13	274.7 31.2–1241	7	0.49 0.11–0.68	4
	85	39.1 32–95.4	3	nc^b
LPV 600 mg	13	1571 807.2–3505	4	0.30 0.22–2.20	3
	85	511.3 61.34–659.4	3	nc^b
LPV 800 mg	13	537.1 247.9–922.9	6	0.21 0.13–0.72	6
EFZ 400 mg	13	3081 1385–9940	10	1.4 0.68–4.14	9
	60	1131 932.3–3514	3	1.84 1.21–2.77	3
	85	10250 628.9–20285	5	1.92 0.86–2.77	4
	110	547 263.7–3666	5	0.83 0.54–1.7	4
EFZ 600 mg	13	3762 2230–6490	55	1.39 1.02–2.31	27
	60	2064 1572–2631	5	2.15 1.79–3.13	5
	85	3707 1939–4521	7	2.27 0.95–4.42	7
NVP 400 mg	13	40.4 22.5–132.4	25	0.0055 0.003–0.0175	20
	85	69.5 30.8–140.3	7	0.064 0.008–0.103	7
	110	7.2 5.8–104	3	0.049 0.013–0.188	3

Time after intake.
^bQuantitative variables are expressed as medians and interquartile ranges ; .
^cNot calculated: no plasma concentration detected.